• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,474.05 209.72
( 0.27%)
Global Indices
Nasdaq
51,705.57 482.31
(0.94%)
Dow Jones
7,575.20 122.74
(1.65%)
Hang Seng
69,318.21 3,298.17
(5.00%)
Nikkei 225
10,435.69 -36.03
(-0.34%)
Forex
USD-INR
94.92 -0.57
(-0.60%)
EUR-INR
109.83 -0.42
(-0.38%)
GBP-INR
127.25 -0.49
(-0.38%)
JPY-INR
0.59 0.00
(-0.48%)

EQUITY - MARKET SCREENER

Jaiprakash Associates Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
532532
INE455F01025
-10.3922244
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JPASSOCIAT
0
591.56
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

astrazeneca pharma india ltd
Lactose India spurts after Q4 PAT climbs 194% YoY to Rs 2 cr
May 20,2026
Revenue from operations soared 64.81% year-on-year to Rs 45.77 crore in the quarter ended 31 March 2026.

Total expenses increased 58.28% year-on-year to Rs 43.67 crore during the quarter, compared with Rs 27.59 crore in the year-ago period. The cost of materials consumed stood at Rs 28.28 crore, up 59.23% YoY, while employee benefits expenses rose 5.37% to Rs 3.53 crore.

Profit before tax (PBT) stood at Rs 2.31 crore in Q4 FY26, registering a growth of 320% from Rs 0.55 crore reported in Q4 FY25.

For the full financial year FY26, the company posted a 17.44% rise in consolidated net profit to Rs 6.06 crore, while revenue rose 40.28% to Rs 163.29 crore compared with FY25.

Lactose (India) is a pharmaceutical company engaged in the business of manufacturing, trading and carrying out job work and manufacturing of pharmaceutical products.